Geninus

Geninus Intangible Assets

The Intangible Assets of Geninus (389030.KQ) as of Oct 24, 2026 is 656.82 M KRW. In the previous year, Intangible Assets was 656.91 M KRW — a change of -0.01% (lower).

Intangible Assets

656.82 MKRW

YoY

-0.01%

Last updated:

Intangible Assets of Geninus is 2022 656.82 M KRW. Intangible Assets of Geninus was 2021 656.91 M KRW. It decreases by -0.01% lower compared to the previous year.

The Geninus Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
1.65 M KRW
Jan 1, 2019
3.25 M KRW
Jan 1, 2020
244.00 M KRW
Jan 1, 2021
656.91 M KRW
Jan 1, 2022
656.82 M KRW
The Geninus Intangible Assets history
YEARIntangible AssetsYoY
656.82 MKRW-0.01%
656.91 MKRW+169.22%
244.00 MKRW+7,406.20%
3.25 MKRW+96.77%
1.65 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geninus Stock analysis

What does Geninus do? Geninus Inc. generates revenue through the provision of single cell analysis services and genetic testing for disease prediction to the public. The company develops and manufactures genome analysis solutions, including cancer genome analysis based on tissue biopsy, and offers personal genetic testing services. Additionally, Geninus Inc. engages in software development and a rental business as part of its product portfolio. The primary customers are individuals seeking genetic insights for health management and healthcare providers requiring advanced genomic analysis tools. The company's products include NGS-based genome analysis technology, cancer genome analysis solutions, and personal genetic testing services. These offerings target healthcare institutions, medical professionals, and consumers interested in personalized health assessments. Geninus Inc. also develops software for genomic data processing, which supports its service delivery and rental business model. Revenue streams are derived from direct sales of genome analysis solutions, service fees for single cell and cancer genome analysis, and subscriptions for software and rental services. The firm's focus on NGS technology positions it within the biotechnology sector, serving both clinical and consumer markets with a range of genomic services and products. Geninus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geninus stock

Intangible Assets of Geninus is 656.82 M KRW in 2022.

Intangible Assets of Geninus changed from 656.91 M KRW to 656.82 M KRW, representing a -0.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Geninus since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Geninus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Geninus

All Key Metrics — Geninus